VIP and COVID-19: Other immunotherapies for diseases such as COVID-19 target the vasoactive intestinal peptide or VIP, which modulates the balance between pro- and anti-inflammatory responses (El Karim et al., 2008; Campos-Salinas et al., 2014; Askar et al., 2020) with promising results.